Table 1 Characteristics of patients
From: Transurethral seminal vesiculoscopy for intractable hematospermia: experience from 144 patients
|  | Patient with hemospermia (n = 144) | |
|---|---|---|
Age (years) | 42 (30.73–52.25) | |
Duration of hemospermia (months) | 12 (12–24) | |
Hypertension | 24/144 (16.67%) | |
DM | 2/144 (1.39%) | |
Chronic hepatitis B | 7/144 (4.86%) | |
Urine routine | ||
Microscopic hematuria | 39/141 (27.46%) | |
 Pyuria | 3/141 (2.11%) | |
 Proteinuria | 6/141 (4.23%) | |
 Sugaruria | 1/141 (0.70%) | |
 Not tested | n = 3 | |
PSA(ng/ml) | 0.72 (0.49–1.13) | |
TRUS/MRI fingding | ||
 Dilatation or enlargement of SV | 70/141 (49.65%) | |
 Hemorrhage | 20/141 (14.18%) | |
 Inflammation of SV | 25/141 (17.73%) | |
 Overall cyst | 52/141 (36.88%) | |
  Prostate | 22/141 (15.60%) | |
  Mullerian duct | 26/141 (18.44%) | |
  Seminal vesicle | 3/141 (2.13%) | |
  Ejaculatory duct | 4/141 (2.84%) | |
 Prostate | 74/141 (52.48%) | |
  Hyperplasia | 42/141 (26.95%) | |
  Enlargement | 25/141 (15.60%) | |
  Inflammation | 7/141 (3.55%) | |
  Stone | 5/141 (1.42%) | |
Nodular | 2/141 (0.71%) | |
 Normal | 10/141 (7.09%) | |
 Not tested | n = 3 |  |
Successful TUSV | 139/144 (96.53%) | |
Follow-up period (days) | 1021.5 (72–2626) | |